Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2001

View Archived Issues

Pharmacological interaction of irofulven and docetaxel under study

Additional MS-325 phase II clinical trial results presented this week

IND opened for the TranStem stem cell expansion system

Bayer worldwide licensing offer

Second orphan drug designation received for orBec in GVHD

First trial of thioredoxin inhibitor initiated in cancer patients

Potent new p38 MAP kinase inhibitor suppresses cytokine release, skin inflammation

Preclinical profile of ML-3000, a new COX/5-LO inhibitor, discussed at Inflammation 2001

UR-8880 exerts potent antiinflammatory effects in the absence of GI toxicity

ABT-627 beneficial in newborn lambs with congenital diaphragmatic hernia and pulmonary hypertension

Surfaxin not associated with changes in fetal human pulmonary cell physiology

Potential therapy for GVHD continues in late-stage clinical development

Irbesartan gives renal protection in type 2 diabetes patients independent of blood pressure effect

Alzheimer's Disease Cooperative Study receives research award from NIA

First IND filed for product emerging from Lilly/Ligand metabolic disease collaboration

Enrollment completed for phase IIa trial of repifermin for mucositis

Development candidate selected by GSK from Cytokinetics' second-generation antimitotics

Phase II trial assessing Angiozyme in combination with chemotherapy initiated

InterMune acquires worldwide rights to oritavancin from Lilly

Inflazyme initiates two trials to study novel antiinflammatory compounds

Genaera receives Cystic Fibrosis Foundation grant to develop Lomucin

Lundbeck presents several classes of 5-HT1A receptor ligands

HIV reverse transcriptase inhibitors described by Pfizer team

Recent U.S. patent covers new sulfonamides and use for atherosclerosis, restenosis

Phosphonic acid-based inhibitors of FBPase synthesized at Metabasis

Inhibitors of cytokine production under development by Hokuriku Seiyaku

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...